Effect of supplementation in treatment of women with polycystic ovary syndrome

Phase 3

• Conditions: Polycystic ovary syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT201609305623N89
• Lead Sponsor: Vice chancellor of research, Bushehr University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

Patients with PCOS according to Rotterdam criteria aged 18 to 40 years

Exclusion Criteria

Pregnant women
Diabetes and impaired glucose tolerance
Hypo or hyperthyroidism
Androgen-secreting tumor
Hyperprolactinemia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PPAR-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;GLUT-1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.

Secondary Outcome Measures

Name	Time	Method
Interleukin 8. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Tumor necrosis factor alpha. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Interleukin 1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;LDLR. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Lp(a). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;TGF-ß. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.